| CPC A61K 38/51 (2013.01) [A61K 31/198 (2013.01); A61P 35/00 (2018.01); C12Q 1/6886 (2013.01); C12Q 1/6869 (2013.01); C12Q 2600/156 (2013.01)] | 10 Claims |
|
1. A method of treating a subject with a therapeutic agent that treats or prevents skin cancer, wherein the subject has skin cancer or is at risk of developing skin cancer, the method comprising:
determining whether the subject has a Histidine Ammonia-Lyase (HAL) variant nucleic acid molecule, wherein the HAL variant nucleic acid molecule is a genomic nucleic acid molecule having a nucleotide sequence comprising an adenine at a position corresponding to position 11,352 according to SEQ ID NO:2, or a guanine at a position corresponding to position 14,441 according to SEQ ID NO:3 encoding a HAL predicted gain-of-function polypeptide by:
obtaining or having obtained a biological sample from the subject; and
performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising the HAL variant nucleic acid molecule encoding the HAL predicted gain-of-function polypeptide; and
administering or continuing to administer the therapeutic agent that treats or prevents skin cancer in a standard dosage amount to a subject that is HAL reference, and/or administering a HAL agonist to the subject that is HAL reference; or
administering or continuing to administer the therapeutic agent that treats or prevents skin cancer in an amount that is the same as or less than a standard dosage amount to a subject that is heterozygous for the HAL variant nucleic acid molecule, and/or administering a HAL agonist to the subject that is heterozygous for the HAL variant nucleic acid molecule;
wherein the presence of a genotype having the HAL variant nucleic acid molecule encoding the HAL predicted gain-of-function polypeptide indicates the subject has a decreased risk of developing skin cancer compared to a subject that does not have the HAL variant nucleic acid molecule encoding the HAL predicted gain-of-function polypeptide.
|